New drugs shake up India's diabetes market

15 January 2024
diabetes-big

The Indian diabetes battleground is experiencing a fresh wave of firepower, with both domestic and multinational pharma giants unleashing a barrage of new anti-diabetic drugs.

From cutting-edge DPP-4 inhibitors to extended-release GLP-1 agonists, these new chips on the block have struck a chord and resonate well, some being priced at a 70% reduction compared to patented drugs, reports The Pharma Letter’s India correspondent.

With an economical alternative to an injectable drug for diabetes and obesity, Glenmark Pharmaceuticals (BOM: 532296) introduced a version of the diabetes medication liraglutide in India, part of the glucagon-like peptide-1 receptor agonists (GLP-1R) class.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars